NorDiag and Hain sign Arrow agreement

Norwegian biotech NorDiag and Hain Lifescience of Germany have signed an OEM agreement for the Arrow instrument and sample preparation reagents to be used with Hain's molecular biological assays.

Norwegian biotech NorDiag and Hain Lifescience of Germany have signed an OEM agreement for the Arrow instrument and sample preparation reagents to be used with Hain's molecular biological assays. Hain currently has a range of assays, including tuberculosis, H-pylori and C-diff. The contract has a minimum yearly purchase commitment. The Arrow is a compact, automated system for nucleic acid extractions.

"This deal is expected to cover approximately 20% of our revenue goals for the Arrow product line until end of 2011," said Marten Wigstol, chief executive of NorDiag.

"The size, capacity and flexibility of the Arrow instrument will allow the customer base an implementation of a smoother workflow," added David Hain, chief executive of Hain Lifescience.

The World Health Organisation (WHO) has officially recommended Hain's GenoType MTBDRplus assay for the simultaneous detection of mycobacterium tuberculosis and its resistance against the major first line drugs in the treatment of tuberculosis.




Companies